Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.
Assistant Professor, Department of Advanced General Dentistry, Dental Hospital, Dankook University, Cheonan, South Korea.
Tae min
Tm
You
Postgraduate Student, Department of Advanced General Dentistry, Dental Hospital, Yonsei University, Seoul, South Korea.
Kang-Hee
KH
Lee
Clinical Associate Professor, Department of Oncology, College of Medicine, Yonsei University, Seoul, South Korea.
Soo-Hyeon
SH
Lee
Associate Professor, Department of Advanced General Dentistry, Dental Hospital, Yonsei University, Seoul, South Korea. Electronic address: Wonse@yuhs.ac.
Wonse
W
Park
D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis* / Q000628:therapy*; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000493:pharmacokinetics*; D001943:Breast Neoplasms / Q000188:drug therapy; D000069448:Denosumab / Q000009:adverse effects* / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008875:Middle Aged
D050071:Bone Density Conservation Agents; D000069448:Denosumab